Welch Group LLC Has $46.27 Million Stock Position in Pfizer Inc. $PFE

Welch Group LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,908,773 shares of the biopharmaceutical company’s stock after purchasing an additional 81,841 shares during the period. Welch Group LLC’s holdings in Pfizer were worth $46,269,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter valued at $27,000. North Capital Inc. acquired a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the first quarter valued at $28,000. Horizon Financial Services LLC acquired a new stake in Pfizer during the first quarter valued at $35,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the first quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $24.81 on Monday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.82. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $141.03 billion, a PE ratio of 13.19, a P/E/G ratio of 0.82 and a beta of 0.55. The stock has a 50-day simple moving average of $24.86 and a 200 day simple moving average of $24.12.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PFE shares. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.